

Chi Chiu Mok

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8950491/chi-chiu-mok-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

187 papers	4,533 citations	41 h-index	60 g-index
215 ext. papers	5,406 ext. citations	4.4 avg, IF	6.23 L-index

#	Paper	IF	Citations
187	The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses.. <i>Journal of Clinical Investigation</i> , 2022 , 132,	15.9	2
186	Estimation of fracture risk by the FRAX tool in patients with systemic lupus erythematosus: a 10-year longitudinal validation study.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X221074451	23.8	1
185	Biologics in Systemic Lupus Erythematosus (SLE) 2022 , 61-73		
184	Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in ANA-positive Chinese patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X2211003	23.8	2
183	Human Complement C4B Allotypes and Deficiencies in Selected Cases With Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2021 , 12, 739430	8.4	1
182	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. <i>Lancet Rheumatology</i> , 2021 ,	14.2	7
181	The Hong Kong Society of Rheumatology Consensus Recommendations for COVID-19 Vaccination in Adult Patients with Autoimmune Rheumatic Diseases. <i>Journal of Clinical Rheumatology and Immunology</i> , 2021 , 21, 7-14	0	2
180	Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial. <i>Bone</i> , 2021 , 146, 115902	4.7	5
179	A Consensus for the Management of Systemic Lupus Erythematosus in Asia. <i>Journal of Clinical Rheumatology and Immunology</i> , 2021 , 21, 1-6	0	1
178	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. <i>International Journal of Rheumatic Diseases</i> , 2021 , 24, 880-895	23.3	2
177	A new old treatment for lupus nephritis. <i>Lancet</i> , 2021 , 397, 2027-2029	40	
176	Gastrointestinal, hepatic, and pancreatic disorders in systemic lupus erythematosus 2021 , 439-449		
175	Imaging Pattern and Outcome of Stroke in Patients With Systemic Lupus Erythematosus: A Case-control Study. <i>Journal of Rheumatology</i> , 2021 , 48, 533-540	4.1	1
174	Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups. <i>Nature Communications</i> , 2021 , 12, 772	17.4	21
173	Does hydroxychloroquine improve patient reported outcomes in patients with lupus?. <i>Lupus</i> , 2021 , 30, 1790-1798	2.6	
172	Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. <i>Nature Communications</i> , 2020 , 11, 2197	17.4	20
171	Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies. <i>Lupus</i> , 2020 , 29, 836-844	2.6	2

170	LB001 EFFICACY AND SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A PHASE 3, RANDOMISED, PLACEBO-CONTROLLED TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35,	4.3	1
169	Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages. <i>Frontiers in Immunology</i> , 2020 , 11, 671	8.4	13
168	Management of glucocorticoid-related osteoporotic vertebral fracture. <i>Osteoporosis and Sarcopenia</i> , 2020 , 6, 1-7	2.3	6
167	Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1070-1076	2.4	15
166	COVID-19 and Rheumatic Diseases: Practical Issues. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020 , 20, 21-24	0	1
165	Glucocorticoid Withdrawal in Lupus Nephritis: A Study Protocol and Literature Review. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020 , 20, 47-55	0	
164	Therapeutic Plasma Exchange in Patients with Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020 , 20, 65-70	0	1
163	The dawn of a new era of therapies in systemic lupus erythematosus. <i>Rheumatology and Immunology Research</i> , 2020 , 1, 31-37	0.2	0
162	Trend of Survival of a Cohort of Chinese Patients With Systemic Lupus Erythematosus Over 25 Years. <i>Frontiers in Medicine</i> , 2020 , 7, 552	4.9	7
161	Rheumatology Drugs and COVID-19. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020 , 20, 1-3	0	
160	Response to: 'Correspondence on 'Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis' by Xu. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	
159	Glucocorticoid-Induced Osteoporosis: The Potential Role of Romosozumab. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020 , 20, 71-79	0	
158	Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. <i>Clinical Rheumatology</i> , 2019 , 38, 3331-3350	3.9	11
157	Metabolic syndrome and systemic lupus erythematosus: the connection. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 765-775	5.1	19
156	Herpes zoster vaccination in systemic lupus erythematosus: the current status. <i>Human Vaccines and Immunotherapeutics</i> , 2019 , 15, 45-48	4.4	14
155	Management of Psychosis in Neuropsychiatric Lupus. <i>Journal of Clinical Rheumatology and Immunology</i> , 2019 , 19, 9-17	0	1
154	Clinical Usefulness of HLA-B*58:01 Genotyping in Gouty Arthritis. <i>Journal of Clinical Rheumatology and Immunology</i> , 2019 , 19, 27-33	0	1
153	Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1663-1668	2.4	9

152	Posterior reversible encephalopathy syndrome as a neuropsychiatric manifestation of systemic lupus erythematosus. <i>Hong Kong Medical Journal</i> , 2019 , 25, 410-412	0.7	1
151	Is Treat-to-target in Lupus Nephritis Realistic in Clinical Practice?. <i>Current Rheumatology Reviews</i> , 2019 , 15, 2-6	1.6	3
150	The 2019 Updated Hong Kong Society of Rheumatology Consensus Statements for the Management of Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology and Immunology</i> , 2019 , 19, 43-46 ^O		
149	Update on Symptomatic Treatment of Acute Vertebral Compression Fracture. <i>Journal of Clinical Rheumatology and Immunology</i> , 2019 , 19, 47-52	0	
148	Cyclophosphamide Versus Obinutuzumab for the Treatment of Anti-MDA5 Positive Inflammatory Myopathy with Interstitial Lung Disease: A Study Protocol and Literature Review. <i>Journal of Clinical Rheumatology and Immunology</i> , 2019 , 19, 53-58	0	
147	Drivers of Satisfaction With Care for Patients With Lupus. <i>ACR Open Rheumatology</i> , 2019 , 1, 649-656	3.5	2
146	Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus. <i>Journal of Autoimmunity</i> , 2019 , 96, 59-73	15.5	24
145	The Jakinibs in systemic lupus erythematosus: progress and prospects. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 85-92	5.9	41
144	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019 , 95, 268-280	9.9	145
143	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019 , 95, 281-295	9.9	87
142	Identification of Low-Abundance Urinary Biomarkers in Lupus Nephritis Using Electrochemiluminescence Immunoassays. <i>Arthritis and Rheumatology</i> , 2019 , 71, 744-755	9.5	10
141	Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019 , 71, 1647-1652	4.7	13
140	Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. <i>Vaccine</i> , 2018 , 36, 3301-3307	4.1	23
139	Morning Stiffness in Elderly Patients with Rheumatoid Arthritis: What is Known About the Effect of Biological and Targeted Agents?. <i>Drugs and Aging</i> , 2018 , 35, 477-483	4.7	3
138	Serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus: a longitudinal cohort analysis. <i>Clinical Rheumatology</i> , 2018 , 37, 2685-2692	3.9	11
137	Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis. <i>Arthritis Research and Therapy</i> , 2018 , 20, 6	5.7	21
136	Systemic lupus erythematosus: what should family physicians know in 2018?. <i>Hong Kong Medical Journal</i> , 2018 , 24, 501-511	0.7	5
135	The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (May 2018). <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2018 , 18, 30-34		1

134	A young lady with inflammation of unknown origin. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2018 , 18, 67-71		
133	The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (Nov 2018). <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2018 , 18, 77-80		
132	Management of immune-related adverse events in patients treated with immune checkpoint inhibitors[Rheumatology point of view. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2018 , 18, 56-60		
131	Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 767-780	5.3	7
130	Clinical presentation, treatment and outcome of Takayasu's arteritis in southern Chinese: a multicenter retrospective study. <i>Rheumatology International</i> , 2018 , 38, 2263-2270	3.6	3
129	Effect of the metabolic syndrome on organ damage and mortality in patients with systemic lupus erythematosus: a longitudinal analysis. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 389-395	2.2	9
128	Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1420-1425	2.4	55
127	Systemic lupus erythematosus: Withdrawing standard of care therapies in SLE trials?. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 328-330	8.1	2
126	Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 677-692	5.1	15
125	Calcineurin inhibitors in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 429-438	5.3	46
124	Intercorrelation between MRI disease activity scores of the sacroiliac joints and the spine, and clinical disease activity indices in patients with axial spondyloarthritis. <i>Reports in Medical Imaging</i> , 2017 , Volume 10, 45-51	0.8	1
123	Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 337	2.8	14
122	Time trend and risk factors of avascular bone necrosis in patients with systemic lupus erythematosus. <i>Lupus</i> , 2017 , 26, 715-722	2.6	15
121	Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 35-41	5.1	21
120	Diagnosis and treatment of primary Sjogren's syndrome: an update. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017 , 17, 6-11		
119	EULAR recommendations for the management of rheumatoid arthritis: what is new in 2017 and its applicability in our local setting. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017 , 17, 47-52		1
118	The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. <i>PLoS ONE</i> , 2017 , 12, e0175207	3.7	63
117	The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (May 2017). <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017 , 17, 29-32		1

116	The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (November 2017). <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017 , 17, 71-75		
115	Dissonance between physicians and patients perspectives on managing impaired morning function in Asian patients with rheumatoid arthritis. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017 , 17, 18-25		
114	Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 891-8	2.4	19
113	Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016 , 68, 1303-9	4.7	22
112	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1052	4.3	
111	Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 30-6	2.4	130
110	Treat-to-target in systemic lupus erythematosus: are we there yet?. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 675-80	3.8	10
109	Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 201-11	5.4	28
108	The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (December 2016). <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2016 , 16, 57-60		
107	FRI0305 Factors Determining Hydroxychloroquine Serum Levels in A Cohort of Chinese Patients with Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 545.3-546	2.4	1
106	Pseudo-Pelger-Hu Nuclear Anomaly in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2513	9.5	
105	Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis. <i>Arthritis Care and Research</i> , 2016 , 68, 1295-302	4.7	58
104	SAT0296 Is Hyperuricemia An Independent Risk Factor for Arterial Thrombosis in Systemic Lupus Erythematosus?. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 775.2-775	2.4	
103	The importance of assessment and management of morning stiffness in Asian patients with rheumatoid arthritis: Recommendations from an expert panel. <i>International Journal of Rheumatic Diseases</i> , 2016 , 19, 30-7	2.3	5
102	Con: Cyclophosphamide for the treatment of lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1053-7	4.3	18
101	Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1561-6	4.3	15
100	Association of depressive/anxiety symptoms with quality of life and work ability in patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 389-95	2.2	23
99	Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. <i>Bone</i> , 2015 , 75, 222-8	4.7	56

98	Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial. <i>Scandinavian Journal of Rheumatology</i> , 2015 , 44, 480-6	1.9	19
97	Mycophenolate mofetil for lupus nephritis: an update. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 1353-64	5.1	29
96	Current role of rituximab in systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 154-63	2.3	37
95	Validation of the LupusPRO in Chinese patients from Hong Kong with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2015 , 67, 297-304	4.7	23
94	OP0264 Factors Associated with Renal Remission, Relapse and Long-Term Renal Function Decline in Lupus Nephritis Treated with Combined Prednisolone and Mycophenolate Mofetil (MMF) or Tacrolimus (TAC). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 171.3-172	2.4	
93	FRI0393 Standardized Incidence Ratio (SIR), time Trend and Risk Factors of Avascular Bone Necrosis (AVN) in Patients with Systemic Lupus Erythematosus (SLE). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 569.2-569	2.4	
92	SAT0394 Can Immunosuppressive Drug Treatment Reduce Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Propensity Score Analysis of a Longitudinal Cohort of 803 Patients?. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 801.3-802	2.4	
91	AB0558 Association of the Metabolic Syndrome (Mets) with Vascular Complications, End Stage Renal Failure (ESRF) and Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Cohort Analysis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1086.3-1087	2.4	
90	THU0308 Use of Complementary and Alternative Medicine (CAM) in Chinese Patients with Rheumatic Diseases: Prevalence and Associated Demographic, Clinical and Social Factors. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 307.2-308	2.4	1
89	FRI0392 Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study?. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 569.1-569	2.4	
88	Gene-based meta-analysis of genome-wide association study data identifies independent single-nucleotide polymorphisms in ANXA6 as being associated with systemic lupus erythematosus in Asian populations. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2966-77	9.5	11
87	Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015 , 17, 67	5.7	5
86	Neuro-ophthalmologic manifestations of systemic lupus erythematosus: a systematic review. <i>International Journal of Rheumatic Diseases</i> , 2014 , 17, 494-501	2.3	20
85	Update on B-cell targeted therapies for systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 773-88	5.4	6
84	Suicidal ideation in patients with systemic lupus erythematosus: incidence and risk factors. <i>Rheumatology</i> , 2014 , 53, 714-21	3.9	31
83	Emerging biological therapies for systemic lupus erythematosus. <i>Expert Opinion on Emerging Drugs</i> , 2014 , 19, 303-22	3.7	19
82	SAT0020 Cross Cultural Adaptation and Validation of Lupuspro in Southern Chinese Patients with Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 596.2-596	2.4	
81	FRI0397 Relationship between IgG Anti-Nr2 Glutamate Receptor Antibodies and Depressive/Anxiety Symptoms in Patients with Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 531.1-531	2.4	

80	SAT0019 Effect of Depressive/Anxiety Symptoms on Quality of Life and Work Disability in Patients with Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 596.1-596	2.4	
79	THU0003 Effect of Renal Damage on Extra-Renal Organ Damage and Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Longitudinal Cohort Study of 756 Patients. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 177.3-177	2.4	
78	Factors associated with withdrawal of the anti-TNF biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry. <i>International Journal of Rheumatic Diseases</i> , 2014 , 17 Suppl 3, 1-8	2.3	11
77	Overview of lupus nephritis management guidelines and perspective from Asia. <i>Nephrology</i> , 2014 , 19, 11-20	2.2	48
76	Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. <i>Lupus</i> , 2013 , 22, 1135-41	2.6	45
75	Overview of lupus nephritis management guidelines and perspective from Asia. <i>International Journal of Rheumatic Diseases</i> , 2013 , 16, 625-36	2.3	25
74	Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 659-64	2.4	134
73	Prevalence and risk factors of low bone mineral density in Chinese patients with systemic sclerosis: a case-control study. <i>Rheumatology</i> , 2013 , 52, 296-303	3.9	28
72	FRI0417 Standardized incidence ratios (SIRS) and risk factors of suicide in chinese patients with rheumatic diseases in hong kong: 1999-2010. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 455.1-455	2.4	
71	AB0646 Serum hepcidin level in systemic lupus erythematosus (SLE): Relationship with disease activity, organ damage and coronary atherosclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 675.14-675	2.4	25
70	High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2013 , 65, 441-7	4.7	34
69	Vitamin D and systemic lupus erythematosus: an update. <i>Expert Review of Clinical Immunology</i> , 2013 , 9, 453-63	5.1	52
68	Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus: a cohort study. <i>Medicine (United States)</i> , 2013 , 92, 217-222	1.8	18
67	Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial. <i>Lupus</i> , 2013 , 22, 1470-8	2.6	14
66	SAT0216 Relationship between individual organ damage and mortality of systemic lupus erythematosus (SLE): A prospective cohort study of 679 patients. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 545.1-545	2.4	1
65	THU0170 The effect of the antiphospholipid syndrome (APS) on survival in 679 patients with sle: A prospective study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 213.1-213	2.4	
64	FRI0252 Severity of skin, tendon and joint damage in chinese patients with systemic sclerosis (SSC) is associated with higher disability and poorer health-related quality of life: A case-control study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 399.3-399	2.4	
63	THU0243 Standardized mortality ratios and predictors of survival in 215 southern chinese patients with inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 237.2-237	2.4	

62	SAT0215 Clinical presentation, treatment and outcome of membranous nephropathy in SLE: A comparison with proliferative lupus glomerulonephritis in 141 patients. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 544.3-545	2.4	
61	AB0453 Retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and predictive factors for drug withdrawal: Data from the hong kong biologics registry. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 663.9-663	2.4	
60	AB0645 Suicidal ideation in patients with systemic lupus erythematosus: Incidence and relationship with anxiety/depression score, disease activity and organ damage. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 675.13-675	2.4	
59	Rituximab for the treatment of rheumatoid arthritis: an update. <i>Drug Design, Development and Therapy</i> , 2013 , 8, 87-100	4.4	78
58	Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. <i>Lupus</i> , 2012 , 21, 36-42	2.6	80
57	Association of CD247 with systemic lupus erythematosus in Asian populations. <i>Lupus</i> , 2012 , 21, 75-83	2.6	24
56	Concurrent psychiatric disorders are associated with significantly poorer quality of life in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2012 , 41, 253-9	1.9	36
55	Understanding lupus nephritis: diagnosis, management, and treatment options. <i>International Journal of Women's Health</i> , 2012 , 4, 213-22	2.8	24
54	Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. <i>Rheumatology</i> , 2012 , 51, 644-52	3.9	81
53	Childhood-onset disease carries a higher risk of low bone mineral density in an adult population of systemic lupus erythematosus. <i>Rheumatology</i> , 2012 , 51, 468-75	3.9	14
52	Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. <i>Clinical Rheumatology</i> , 2011 , 30, 303-12	3.9	29
51	Erythema elevatum diutinum in systemic lupus erythematosus. <i>Rheumatology International</i> , 2011 , 31, 259-62	3.6	13
50	Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. <i>Arthritis Care and Research</i> , 2011 , 63, 195-202	4.7	130
49	Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. <i>Arthritis Care and Research</i> , 2011 , 63, 875-83	4.7	44
48	Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese. <i>Lupus</i> , 2011 , 20, 767-76	3.6	66
47	Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 778-84	2.4	51
46	Moyamoya phenomenon in systemic lupus erythematosus. <i>Rheumatology</i> , 2011 , 50, 1931	3.9	5
45	Biomarkers for lupus nephritis: a critical appraisal. <i>Journal of Biomedicine and Biotechnology</i> , 2010 , 2010, 638413		111

44	Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus. <i>Translational Research</i> , 2010 , 156, 320-5	11	34
43	Minimal mesangial lupus nephritis: a systematic review. <i>Scandinavian Journal of Rheumatology</i> , 2010 , 39, 181-9	1.9	20
42	Update on emerging drug therapies for systemic lupus erythematosus. <i>Expert Opinion on Emerging Drugs</i> , 2010 , 15, 53-70	3.7	15
41	Prevalence and Determinants of Psychiatric Disorders in Patients With Rheumatoid Arthritis. <i>Psychosomatics</i> , 2010 , 51, 338-338.e8	2.6	4
40	Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2010 , 39, 42-9	1.9	50
39	Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2010 , 29, 599-604	3.9	14
38	Prevalence and determinants of psychiatric disorders in patients with rheumatoid arthritis. <i>Psychosomatics</i> , 2010 , 51, 338-338.e8	2.6	64
37	Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. <i>Lupus</i> , 2009 , 18, 1091-5	2.6	37
36	Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. <i>Nature Reviews Nephrology</i> , 2009 , 5, 212-20	14.9	46
35	Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2009 , 38, 362-8	1.9	49
34	Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study. <i>Bone</i> , 2008 , 43, 327-331	4.7	34
33	Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus. <i>Lupus</i> , 2008 , 17, 1018-22	2.6	12
32	Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. <i>Lupus</i> , 2008 , 17, 1103-7	2.6	40
31	Who should treat lupus nephritis: rheumatologists or nephrologists?. <i>Nature Clinical Practice Nephrology</i> , 2008 , 4, E1		1
30	Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. <i>Journal of Rheumatology</i> , 2008 , 35, 172-4	4.1	45
29	Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. <i>Journal of Rheumatology</i> , 2008 , 35, 1978-82	4.1	59
28	Management of systemic lupus erythematosus in Chinese patients. <i>Expert Review of Clinical Immunology</i> , 2007 , 3, 925-35	5.1	4
27	Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study. <i>Medicine (United States)</i> , 2007 , 86, 203-209	1.8	20

26	Rituximab for refractory polymyositis: an open-label prospective study. <i>Journal of Rheumatology</i> , 2007 , 34, 1864-8	4.1	62
25	Therapeutic options for resistant lupus nephritis. <i>Seminars in Arthritis and Rheumatism</i> , 2006 , 36, 71-81	5.3	43
24	Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. <i>Medicine (United States)</i> , 2006 , 85, 221-228	1.8	43
23	Emerging drug therapies for systemic lupus erythematosus. <i>Expert Opinion on Emerging Drugs</i> , 2006 , 11, 597-608	3.7	6
22	Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. <i>American Journal of Medicine</i> , 2006 , 119, 355.e25-33	2.4	108
21	Biological therapies for rheumatoid arthritis: beyond TNF-blockade. <i>APLAR Journal of Rheumatology</i> , 2006 , 9, 200-205		1
20	Non-tumor necrosis factor biological therapies for rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , 2005 , 8, 77-83		2
19	Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. <i>Kidney International</i> , 2005 , 68, 813-7	9.9	109
18	Investigations and management of gastrointestinal and hepatic manifestations of systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 741-66	5.3	34
17	Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2774-82		164
16	Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3997-4002		33
15	Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. <i>Medicine (United States)</i> , 2005 , 84, 218-224	1.8	135
14	Therapeutic advances in rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , 2004 , 7, 62-70		2
13	Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. <i>American Journal of Kidney Diseases</i> , 2004 , 43, 269-76	7.4	58
12	Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2559-68		136
11	Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. <i>American Journal of Medicine</i> , 2004 , 117, 791-5	2.4	43
10	Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. <i>Scandinavian Journal of Rheumatology</i> , 2003 , 32, 181-3	1.9	30
9	Rheumatoid-like polyarthritis as a presenting feature of metastatic carcinoma: a case presentation and review of the literature. <i>Clinical Rheumatology</i> , 2003 , 22, 353-4	3.9	22

8	Mucormycosis in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2003 , 33, 115-24	5.3	24
7	Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. <i>American Journal of Medicine</i> , 2003 , 115, 59-62	2.4	66
6	Scleroderma renal crisis sine scleroderma during pregnancy. <i>Scandinavian Journal of Rheumatology</i> , 2003 , 32, 55-7	1.9	11
5	Damage accrual in southern Chinese patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2003 , 30, 1513-9	4.1	68
4	Mycophenolate mofetil in lupus glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2002 , 40, 447-54	5.7	43
3	Behçet's disease in southern Chinese patients. <i>Journal of Rheumatology</i> , 2002 , 29, 1689-93	4.1	22
2	Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. <i>American Journal of Kidney Diseases</i> , 1999 , 34, 315-23	7.4	97
1	Osteoporosis in Rheumatic Diseases. <i>Journal of Clinical Rheumatology and Immunology</i> , 1-8	0	